Lupus erythematosus can be treated with rituximab, a biologic agent. Rituximab is a monoclonal antibody, which can be used for the treatment of chronic lymphocytic leukemia, Hodgkin’s lymphoma and lupus erythematosus and other immune diseases in the clinic, and can also be used for the treatment of rheumatoid arthritis, vasculitis granulomatosa and so on. During the use of the drug, it is important to note that it is contraindicated in patients who are allergic to the components of the product and excipients, active infections, severe cardiac failure, pregnancy and lactation in women. The use of such drugs is associated with a large number of adverse reactions, the most common of which are fatigue, flushing, hypertension, neutropenia, lymphopenia, leukopenia, elevated ghrelin, bacterial infections, muscle spasms, joint pain, hepatitis B, fungal infections, upper respiratory tract infections. The use of biologics in lupus erythematosus can inhibit T-cell activation and induce T-cell tolerance, inhibit complement activation, and have some effect in clinical application. It is recommended that patients with lupus erythematosus go to the hospital in a timely manner, under the guidance of the doctor to use the appropriate drugs, do not self-medication.